UBS Group Increases Encompass Health (NYSE:EHC) Price Target to $100.00

Encompass Health (NYSE:EHC) had its target price raised by analysts at UBS Group from $96.00 to $100.00 in a report issued on Thursday, MarketBeat.com reports. The brokerage presently has a “buy” rating on the stock. UBS Group’s target price indicates a potential upside of 16.66% from the stock’s previous close.

A number of other analysts also recently commented on EHC. Barclays dropped their price objective on Encompass Health from $113.00 to $109.00 and set an “overweight” rating for the company in a report on Tuesday. Stephens restated an “overweight” rating and set a $105.00 price objective on shares of Encompass Health in a report on Tuesday. Royal Bank of Canada upped their price objective on Encompass Health from $83.00 to $95.00 and gave the stock an “outperform” rating in a report on Wednesday, May 22nd. Leerink Partnrs upgraded Encompass Health to a “strong-buy” rating in a report on Wednesday, July 10th. Finally, Truist Financial increased their price target on Encompass Health from $95.00 to $100.00 and gave the company a “buy” rating in a report on Monday, July 15th. Nine research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $99.88.

Encompass Health Trading Down 1.6 %

EHC traded down $1.37 during trading on Thursday, hitting $85.72. The company’s stock had a trading volume of 759,313 shares, compared to its average volume of 659,747. The firm’s 50 day moving average price is $86.48 and its 200-day moving average price is $81.59. The company has a debt-to-equity ratio of 1.14, a current ratio of 1.37 and a quick ratio of 1.37. The stock has a market cap of $8.63 billion, a PE ratio of 23.17, a PEG ratio of 1.45 and a beta of 0.89. Encompass Health has a twelve month low of $57.55 and a twelve month high of $94.38.

Encompass Health (NYSE:EHC) last issued its quarterly earnings results on Monday, August 5th. The company reported $1.11 earnings per share for the quarter, beating the consensus estimate of $1.01 by $0.10. The company had revenue of $1.30 billion during the quarter, compared to the consensus estimate of $1.30 billion. Encompass Health had a return on equity of 18.01% and a net margin of 7.60%. Encompass Health’s revenue was up 9.6% on a year-over-year basis. During the same period in the previous year, the firm posted $0.95 EPS. On average, analysts expect that Encompass Health will post 4.09 earnings per share for the current year.

Insider Buying and Selling at Encompass Health

In other Encompass Health news, insider Elissa Joy Charbonneau sold 10,000 shares of the company’s stock in a transaction dated Friday, May 24th. The shares were sold at an average price of $85.02, for a total value of $850,200.00. Following the completion of the transaction, the insider now directly owns 18,594 shares of the company’s stock, valued at approximately $1,580,861.88. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 2.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Encompass Health

Several large investors have recently modified their holdings of EHC. TD Asset Management Inc lifted its position in shares of Encompass Health by 239.6% during the fourth quarter. TD Asset Management Inc now owns 1,969,186 shares of the company’s stock worth $131,384,000 after purchasing an additional 1,389,275 shares during the last quarter. 8 Knots Management LLC bought a new stake in shares of Encompass Health in the 4th quarter worth approximately $75,424,000. Norges Bank bought a new position in Encompass Health during the 4th quarter worth $69,178,000. Epoch Investment Partners Inc. lifted its stake in Encompass Health by 102.9% in the fourth quarter. Epoch Investment Partners Inc. now owns 1,399,341 shares of the company’s stock valued at $93,364,000 after buying an additional 709,593 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its position in shares of Encompass Health by 614.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 540,519 shares of the company’s stock worth $44,637,000 after acquiring an additional 464,897 shares during the last quarter. Institutional investors own 97.25% of the company’s stock.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.